 |
|
Nonalcoholic fatty liver disease in children and adolescents
Hae Sang Lee
Clin Exp Pediatr. 2024;67(2):90-91. Published online 2024 Jan 24 DOI: https://doi.org/10.3345/cep.2023.00752
|
|
Citations to this article as recorded by
 Hepatic Histopathological Benefit, Microbial Cost: Oral Vancomycin Mitigates Non-Alcoholic Fatty Liver Disease While Disrupting the Cecal Microbiota
Gül Çirkin, Selma Aydemir, Burcu Açıkgöz, Aslı Çelik, Yunus Güler, Müge Kiray, Başak Baykara, Ener Çağrı Dinleyici, Yeşim Öztürk
International Journal of Molecular Sciences.2025; 26(17): 8616. CrossRef Effects of a polypill on circulating levels of resistin and visfatin in men with non-alcoholic fatty liver disease: A five-year clinical trial
Mahdieh Nazari-Robati, Tania Dehesh, Beydolah Shahouzehi, Gholamreza Roshandel, Hossein Poustchi, Solaleh Emamgholipour, Aleksandra Klisic
PLOS One.2025; 20(10): e0331121. CrossRef Impact of Comorbid Polycystic Ovary Syndrome on Clinical and Laboratory Parameters in Female Adolescents with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Cross-Sectional Study
Murat Keskin, Hanife Aysegul Arsoy, Ozlem Kara, Emre Sarandol, Nizameddin Koca, Yusuf Yilmaz
Journal of Clinical Medicine.2024; 13(19): 5885. CrossRef Fasting intact insulin by mass spectrometry is associated with metabolic dysfunction–associated steatotic liver disease in youth
Helaina E. Huneault, Jaclyn S. Lo, Shasha Bai, Zhulin He, Michael J. McPhaul, Fernando Bril, Miriam B. Vos, Melanie G. Cree
Hepatology Communications.2024;[Epub] CrossRef
|